Topics

Following Reorganization, Pfizer Posts Growth in First Quarter

20:00 EDT 29 Apr 2019 | BioSpace

Pfizer closed out the first quarter of 2019 with revenues of $13.1 billion driven by a significant 36 percent global growth of Eliquis sales, a 34 percent increase in Xeljanz revenue and a 25 percent increase in sales of Ibrance, the company announced this morning.

Original Article: Following Reorganization, Pfizer Posts Growth in First Quarter

NEXT ARTICLE

More From BioPortfolio on "Following Reorganization, Pfizer Posts Growth in First Quarter"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...